^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
11/24/2021
Excerpt:
SYSTEMIC ADJUVANT TREATMENT: HR-NEGATIVE - HER2-NEGATIVE DISEASE...Addition of 1 year of adjuvant olaparib is an option for select patients with germline BRCA1/2 mutation after completion of adjuvant chemotherapy.
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

176P - Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)

Published date:
07/14/2020
Excerpt:
Regardless of the treatment arm, pCR rates were higher in HR- than in HR+ pts (57.9%, 44/76 vs. 41.4%, 12/29;). We observed highest pCR rates in HR- pts with BRCA1/2 mutations (65.8%, 25/38) and lowest in HR+ pts without BRCA1/2 mutations (0%, 0/8).
Secondary therapy:
paclitaxel
Trial ID: